Loading...
Loading...
Browse all stories on DeepNewz
VisitFirst Therapeutic Area Targeted by Xaira's RFdiffusion Technology
Oncology • 25%
Neurodegenerative Diseases • 25%
Cardiovascular Diseases • 25%
Infectious Diseases • 25%
Company announcements or major biotech industry publications.
Xaira, Led by CEO Marc Tessier-Lavigne, Raises $1B for RFdiffusion Tech
Apr 25, 2024, 12:25 AM
Xaira, a new biotechnology company, has successfully raised over $1 billion in committed capital, marking one of the largest funding rounds in biotech history. The company, led by CEO Marc Tessier-Lavigne, is set to focus on next-generation technology in biopharma, leveraging AI and RFdiffusion from David Baker's lab. The funding round saw participation from major venture capital firms including Arch, Foresite, F-Prime, NEA, Sequoia, Lux, Lightspeed, and Two Sigma. This significant financial backing underscores the growing interest and investment in tech-driven biopharma solutions.
View original story
Cancer • 25%
Alzheimer's Disease • 25%
Cystic Fibrosis • 25%
Sickle Cell Disease • 25%
Cardiovascular diseases • 25%
Neurodegenerative diseases • 25%
Cancer • 25%
Rare genetic disorders • 25%
Cancer • 20%
Rare genetic disorders • 20%
Heart disease • 20%
Neurological disorders • 20%
Other • 20%
Cancer Detection • 20%
Cardiac Imaging • 20%
Neurological Scans • 20%
Musculoskeletal Imaging • 20%
Other Applications • 20%
Cancer • 25%
Rare Genetic Disorders • 25%
Heart Disease • 25%
Neurodegenerative Diseases • 25%
Alzheimer's Disease • 25%
Parkinson's Disease • 25%
Diabetes • 25%
Osteoporosis • 25%
Liver Disease • 25%
Cystic Fibrosis • 25%
Muscular Dystrophy • 25%
Hemophilia • 25%
Automotive • 25%
Healthcare • 25%
Manufacturing • 25%
Agriculture • 25%
Therapeutic applications • 25%
Research tools • 25%
Diagnostic tools • 25%
Personalized medicine • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of World • 25%
Healthcare • 20%
Automotive • 20%
Finance • 20%
Retail • 20%
Energy • 20%
Cancer • 25%
Neurodegenerative Diseases • 25%
Infectious Diseases • 25%
Genetic Disorders • 25%